– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – – Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers – – NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Bo ...

RealPeopleGroup/E+ via Getty Images The best I can say about Esperion Therapeutics, Inc. (NASDAQ:ESPR) the stock is that at least it is (barely) clinging to a trading range. The best I can say about Esperion Therapeutics the company is that the business is still delivering on its promises. Meeting Expectations Esperion reported Q2 2024 earnings last week. While the stock responded with an 8.9% loss (which has almost reversed at the time of writing), the earnings results are what investors should have expect ...

Rasi Bhadramani Investment Thesis l am bullish on Esperion Therapeutios, Inc.(NASDAQ:ESPR) and rate it a buy given its strategic initiatives and markt pocential, which present an upbeat road map for sustain +52% Growth vs. 2Q23 $7.5 $33 528.3 2Q23 3Q23 4Q23 1Q24 2Q24 = U.S. Product Revenue ■ Royalty Revenue ESPR Q2 2024 Presentation These initiatives among other initiatives have seen the company register strong revenue growth and margin expansions particularly gross margins from Q4 2022 to Q2 2024 reported ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Betty Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham Cameron Bozdog - Bank of America Operator Ladies and gentlemen. Thank you for standing by. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdiction o ...

Esperion Therapeutics, Inc. (ESPR) incurred a loss of 5 cents per share for the second quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 15 cents. The company had incurred a loss of 46 cents per share in the year-ago quarter. Esperion generated revenues of $73.8 million, up nearly 186% year over year, driven by higher collaboration revenues and product revenues in the United States. The reported figure beat the Zacks Consensus Estimate of $52 million. Quarter in Detail Esper ...

ESPERION REACHING GOALS Q2 2024 Earnings Presentation August 12, 2024 Forward-looking Statements & Disclosures This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its r ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.08 per share when it actually produced earnings of $0.34, delivering a surprise of 525%. Over the last four quarters ...

Exhibit 99.1 Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 ...

– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Re ...